Niki BioSolutions, Inc. NIKI
Annual
Quarterly
FY2023 · ended Dec 31, 2023 · Revenue $431,378 · Filed Mar 27, 2026
Niki BioSolutions, Inc. (NIKI) files with the SEC under industry code 3829, Measuring & Controlling Devices, NEC. As of Dec 31, 2025 it held $18.6 million in cash and investments and $24,428 in total debt.
Revenue
$431,378
Net income
$-1.36M
+68.1% vs prior year
Operating cash flow
$-1.84M
-54.4% vs prior year
Free cash flow
$-7.73M
+38.2% vs prior year
EPS
$-0.19
+75.6% vs prior year
Dividend per share
None
Shares outstanding
—
Net cash
$18.53M
FY 2025
Operating margin
—
Company profile
- Industry
- Measuring & Controlling Devices, NEC (SIC 3829)
- Listed as
- NIKI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1734005
- Former names
- Aptorum Group Ltd (until Jun 22, 2026)
Other Measuring & Controlling Devices, NEC companies
- Thermo Fisher Scientific Inc. TMO
- Rockwell Automation, Inc ROK
- Trimble Inc. TRMB
- Onto Innovation Inc. ONTO
- Mirion Technologies, Inc. MIR
- Quantum-Si Inc QSI
- Owlet, Inc. OWLT
- Geospace Technologies Corp GEOS
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $431,378 | — | — |
| Net income | -$1.4M | -$4.3M | -$2.8M | -$9.8M | -$25.0M |
| Diluted EPS | -$0.19 | -$0.78 | -$0.62 | -$2.75 | -$7.15 |
| Operating cash flow | -$1.8M | -$1.2M | -$7.7M | -$12.3M | -$14.7M |
| Free cash flow | — | — | -$7.7M | -$12.5M | -$14.8M |
| Total assets | $18.7M | $16.1M | $20.6M | $20.9M | $21.9M |
| Total liabilities | $4.9M | $4.4M | $5.3M | $13.0M | $4.4M |
| Stockholders' equity | $23.1M | $21.1M | $24.8M | $15.7M | $23.6M |
| Cash and investments | $18.6M | $15.1M | $16.1M | $102,481 | — |
| Total debt | $24,428 | $116,407 | $224,717 | $471,179 | $513,392 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K/A | Amended current report | Aug 21, 2026 | Jul 20, 2026 |
| 8-K | Current report | Aug 21, 2026 | Aug 21, 2026 |
All 258 Niki BioSolutions, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.